| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
|
J Clin Oncol
|
2007
|
12.62
|
|
2
|
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
|
Clin Cancer Res
|
2007
|
9.21
|
|
3
|
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
|
J Clin Oncol
|
2008
|
6.64
|
|
4
|
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
|
J Clin Oncol
|
2010
|
6.30
|
|
5
|
Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.
|
J Clin Oncol
|
2007
|
4.42
|
|
6
|
Phase II trial of gefitinib in recurrent glioblastoma.
|
J Clin Oncol
|
2003
|
3.83
|
|
7
|
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.
|
Ann Thorac Surg
|
2006
|
3.76
|
|
8
|
Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial.
|
Lancet
|
2010
|
3.07
|
|
9
|
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
|
Cancer Res
|
2006
|
3.02
|
|
10
|
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.
|
Ann Surg Oncol
|
2006
|
2.69
|
|
11
|
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
|
J Clin Oncol
|
2006
|
2.60
|
|
12
|
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
|
J Clin Oncol
|
2005
|
2.48
|
|
13
|
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
|
J Natl Cancer Inst
|
2006
|
2.34
|
|
14
|
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
|
J Clin Oncol
|
2008
|
2.32
|
|
15
|
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
|
J Clin Oncol
|
2006
|
2.29
|
|
16
|
Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation.
|
Radiology
|
2004
|
2.21
|
|
17
|
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
|
J Clin Oncol
|
2007
|
2.20
|
|
18
|
Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.
|
J Clin Oncol
|
2004
|
2.18
|
|
19
|
Phase II trial of temozolomide in patients with progressive low-grade glioma.
|
J Clin Oncol
|
2003
|
2.16
|
|
20
|
Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.
|
Cancer
|
2003
|
2.06
|
|
21
|
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.
|
Cancer
|
2009
|
2.06
|
|
22
|
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
2.02
|
|
23
|
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
|
Neuro Oncol
|
2010
|
1.99
|
|
24
|
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
|
J Clin Oncol
|
2002
|
1.93
|
|
25
|
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.
|
Chest
|
2005
|
1.89
|
|
26
|
Panel of serum biomarkers for the diagnosis of lung cancer.
|
J Clin Oncol
|
2007
|
1.86
|
|
27
|
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
|
J Clin Oncol
|
2005
|
1.85
|
|
28
|
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
|
Int J Radiat Oncol Biol Phys
|
2004
|
1.83
|
|
29
|
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2002
|
1.80
|
|
30
|
Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
|
J Surg Oncol
|
2006
|
1.75
|
|
31
|
Use of tablet personal computers for sensitive patient-reported information.
|
J Support Oncol
|
2009
|
1.73
|
|
32
|
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
|
J Natl Cancer Inst
|
2005
|
1.70
|
|
33
|
Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.
|
J Thorac Cardiovasc Surg
|
2005
|
1.69
|
|
34
|
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
|
Mol Cancer Ther
|
2009
|
1.67
|
|
35
|
Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data.
|
Health Serv Res
|
2008
|
1.65
|
|
36
|
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
|
J Neurosurg
|
2010
|
1.65
|
|
37
|
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
|
J Neurooncol
|
2009
|
1.65
|
|
38
|
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
|
Clin Cancer Res
|
2011
|
1.64
|
|
39
|
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
|
J Clin Oncol
|
2005
|
1.63
|
|
40
|
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
|
J Neurooncol
|
2003
|
1.63
|
|
41
|
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
|
Clin Cancer Res
|
2006
|
1.63
|
|
42
|
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.
|
J Clin Oncol
|
2012
|
1.61
|
|
43
|
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
|
Neuro Oncol
|
2008
|
1.59
|
|
44
|
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
|
Neuro Oncol
|
2010
|
1.59
|
|
45
|
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
|
Blood
|
2011
|
1.54
|
|
46
|
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
|
J Clin Oncol
|
2005
|
1.53
|
|
47
|
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
|
J Clin Oncol
|
2009
|
1.53
|
|
48
|
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
|
Clin Cancer Res
|
2005
|
1.52
|
|
49
|
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
|
J Clin Oncol
|
2002
|
1.50
|
|
50
|
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
|
Clin Cancer Res
|
2005
|
1.46
|
|
51
|
Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.
|
J Pain Symptom Manage
|
2009
|
1.45
|
|
52
|
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
|
Clin Cancer Res
|
2006
|
1.41
|
|
53
|
Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.
|
AJR Am J Roentgenol
|
2002
|
1.41
|
|
54
|
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
|
Oncotarget
|
2014
|
1.40
|
|
55
|
SEER insights.
|
J Neurosurg
|
2013
|
1.40
|
|
56
|
Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer.
|
Cancer
|
2010
|
1.40
|
|
57
|
Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.
|
Ann Surg
|
2005
|
1.39
|
|
58
|
Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.
|
J Pain Symptom Manage
|
2010
|
1.39
|
|
59
|
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
|
Neuro Oncol
|
2007
|
1.39
|
|
60
|
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
|
J Clin Oncol
|
2008
|
1.38
|
|
61
|
Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
|
J Natl Cancer Inst
|
2002
|
1.37
|
|
62
|
Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2003
|
1.36
|
|
63
|
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
|
Clin Cancer Res
|
2008
|
1.35
|
|
64
|
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
|
J Clin Oncol
|
2002
|
1.32
|
|
65
|
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
|
Cancer
|
2009
|
1.29
|
|
66
|
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
|
J Clin Oncol
|
2005
|
1.29
|
|
67
|
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
|
J Neurooncol
|
2011
|
1.29
|
|
68
|
Bevacizumab and daily temozolomide for recurrent glioblastoma.
|
Cancer
|
2011
|
1.28
|
|
69
|
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
|
J Neurooncol
|
2010
|
1.26
|
|
70
|
Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.
|
Lung Cancer
|
2011
|
1.26
|
|
71
|
Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.
|
J Mol Diagn
|
2003
|
1.25
|
|
72
|
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
|
Clin Cancer Res
|
2013
|
1.22
|
|
73
|
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
|
Cancer
|
2005
|
1.21
|
|
74
|
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.
|
J Clin Oncol
|
2011
|
1.21
|
|
75
|
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
|
J Immunol Methods
|
2008
|
1.19
|
|
76
|
Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804.
|
Psychooncology
|
2009
|
1.17
|
|
77
|
Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer.
|
J Appl Physiol (1985)
|
2009
|
1.17
|
|
78
|
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
|
J Natl Compr Canc Netw
|
2011
|
1.16
|
|
79
|
The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
|
Cancer Res
|
2007
|
1.16
|
|
80
|
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
|
Cancer
|
2011
|
1.16
|
|
81
|
Pulmonary vein diameter, cross-sectional area, and shape: CT analysis.
|
Radiology
|
2005
|
1.16
|
|
82
|
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
|
Cancer Med
|
2013
|
1.13
|
|
83
|
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.
|
Mol Cancer Ther
|
2006
|
1.13
|
|
84
|
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
|
J Clin Oncol
|
2006
|
1.12
|
|
85
|
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.
|
Dis Colon Rectum
|
2008
|
1.12
|
|
86
|
Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.
|
J Neurooncol
|
2009
|
1.11
|
|
87
|
Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
|
Int J Radiat Oncol Biol Phys
|
2013
|
1.11
|
|
88
|
Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors.
|
Neuro Oncol
|
2008
|
1.11
|
|
89
|
Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.
|
Cancer
|
2007
|
1.11
|
|
90
|
Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238.
|
J Thorac Oncol
|
2007
|
1.10
|
|
91
|
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
|
J Neurooncol
|
2007
|
1.10
|
|
92
|
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
|
Lung Cancer
|
2004
|
1.10
|
|
93
|
Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.
|
J Oncol Pract
|
2009
|
1.10
|
|
94
|
Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients.
|
Support Care Cancer
|
2011
|
1.08
|
|
95
|
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
|
PLoS One
|
2012
|
1.08
|
|
96
|
Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.
|
J Thorac Cardiovasc Surg
|
2002
|
1.08
|
|
97
|
Phase II study of carboplatin in children with progressive low-grade gliomas.
|
J Clin Oncol
|
2002
|
1.07
|
|
98
|
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.07
|
|
99
|
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
|
Cancer
|
2005
|
1.07
|
|
100
|
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
|
PLoS One
|
2013
|
1.07
|
|
101
|
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
|
J Neurooncol
|
2010
|
1.06
|
|
102
|
Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.
|
Lung Cancer
|
2005
|
1.05
|
|
103
|
Temozolomide in children with progressive low-grade glioma.
|
Neuro Oncol
|
2007
|
1.05
|
|
104
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2009
|
1.04
|
|
105
|
Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study.
|
Cancer
|
2006
|
1.03
|
|
106
|
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
|
J Neurooncol
|
2011
|
1.02
|
|
107
|
Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients.
|
Support Care Cancer
|
2010
|
1.01
|
|
108
|
Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.
|
Lung Cancer
|
2004
|
1.01
|
|
109
|
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
|
Cancer
|
2009
|
1.01
|
|
110
|
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
|
J Neurooncol
|
2012
|
1.00
|
|
111
|
Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer.
|
BMC Cancer
|
2010
|
1.00
|
|
112
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
Cancer
|
2003
|
1.00
|
|
113
|
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
|
Clin Lung Cancer
|
2005
|
1.00
|
|
114
|
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
|
Nucl Med Biol
|
2011
|
0.99
|
|
115
|
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
|
Neuro Oncol
|
2008
|
0.99
|
|
116
|
Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.
|
Cancer
|
2002
|
0.99
|
|
117
|
Economic outcomes of breast cancer survivorship: CALGB study 79804.
|
Breast Cancer Res Treat
|
2005
|
0.98
|
|
118
|
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
|
J Neurooncol
|
2011
|
0.98
|
|
119
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
Cancer
|
2004
|
0.97
|
|
120
|
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
|
Med Care
|
2008
|
0.96
|
|
121
|
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
|
BMC Cancer
|
2010
|
0.96
|
|
122
|
Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.
|
Am J Surg
|
2005
|
0.96
|
|
123
|
A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
|
Am J Clin Oncol
|
2005
|
0.95
|
|
124
|
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.
|
Radiology
|
2002
|
0.95
|
|
125
|
Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study.
|
Psychooncology
|
2011
|
0.95
|
|
126
|
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.
|
Psychooncology
|
2008
|
0.95
|
|
127
|
Clinicopathologic study of 85 cases of melanoma of the female genitalia.
|
J Am Acad Dermatol
|
2012
|
0.94
|
|
128
|
Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.
|
BMC Cancer
|
2008
|
0.93
|
|
129
|
Molecular markers of prognosis in astrocytic tumors.
|
Cancer
|
2002
|
0.93
|
|
130
|
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
|
Lung Cancer
|
2005
|
0.93
|
|
131
|
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
|
Cancer Immunol Immunother
|
2013
|
0.92
|
|
132
|
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
|
Cancer Immunol Immunother
|
2007
|
0.92
|
|
133
|
Survival analysis of presumptive prognostic markers among oligodendrogliomas.
|
Cancer
|
2005
|
0.92
|
|
134
|
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
|
Neuro Oncol
|
2004
|
0.91
|
|
135
|
Poor documentation prevents adequate assessment of quality metrics in colorectal cancer.
|
J Oncol Pract
|
2009
|
0.91
|
|
136
|
Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial.
|
Acta Oncol
|
2013
|
0.91
|
|
137
|
Safety and efficacy of weekly oral oltipraz in chronic smokers.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.90
|
|
138
|
Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
|
Int J Cancer
|
2010
|
0.90
|
|
139
|
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
|
J Neurooncol
|
2012
|
0.89
|
|
140
|
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.89
|
|
141
|
Biomarkers to help guide management of patients with pulmonary nodules.
|
Am J Respir Crit Care Med
|
2013
|
0.89
|
|
142
|
The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study.
|
Breast Cancer Res Treat
|
2013
|
0.88
|
|
143
|
Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761.
|
Clin Cancer Res
|
2003
|
0.87
|
|
144
|
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
|
Clin Cancer Res
|
2009
|
0.87
|
|
145
|
Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804.
|
Cancer
|
2009
|
0.87
|
|
146
|
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
|
Neuro Oncol
|
2009
|
0.87
|
|
147
|
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
|
J Neurooncol
|
2009
|
0.86
|
|
148
|
[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma.
|
Neurosurgery
|
2004
|
0.86
|
|
149
|
Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804.
|
J Cancer Surviv
|
2008
|
0.86
|
|
150
|
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
|
Neuro Oncol
|
2004
|
0.86
|
|
151
|
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
|
Neuro Oncol
|
2006
|
0.85
|
|
152
|
Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study.
|
Appl Physiol Nutr Metab
|
2013
|
0.85
|
|
153
|
Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.
|
Neurol Res
|
2009
|
0.84
|
|
154
|
Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.
|
J Neurooncol
|
2014
|
0.84
|
|
155
|
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.
|
Breast Cancer Res Treat
|
2014
|
0.84
|
|
156
|
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
|
J Clin Oncol
|
2004
|
0.84
|
|
157
|
Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.
|
PLoS One
|
2013
|
0.83
|
|
158
|
Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.
|
J Mol Diagn
|
2004
|
0.83
|
|
159
|
Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
|
Support Care Cancer
|
2014
|
0.83
|
|
160
|
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
|
J Neurooncol
|
2011
|
0.82
|
|
161
|
Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.
|
J Thorac Oncol
|
2013
|
0.82
|
|
162
|
Treatment-related toxicity and supportive care in metastatic colorectal cancer.
|
J Support Oncol
|
2010
|
0.82
|
|
163
|
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
|
J Nucl Med
|
2006
|
0.82
|
|
164
|
Quality of life outcomes are equivalent after lobectomy in the elderly.
|
J Thorac Cardiovasc Surg
|
2008
|
0.82
|
|
165
|
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
|
Cancer
|
2012
|
0.81
|
|
166
|
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
|
J Thorac Oncol
|
2008
|
0.81
|
|
167
|
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
|
J Thorac Oncol
|
2007
|
0.81
|
|
168
|
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
|
Cancer
|
2009
|
0.81
|
|
169
|
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
|
J Neurooncol
|
2011
|
0.81
|
|
170
|
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
|
Neuro Oncol
|
2008
|
0.80
|
|
171
|
Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
|
Lung Cancer
|
2004
|
0.80
|
|
172
|
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
|
Lung Cancer
|
2005
|
0.80
|
|
173
|
Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).
|
Clin Lung Cancer
|
2002
|
0.80
|
|
174
|
A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.
|
J Neurosurg
|
2014
|
0.80
|
|
175
|
Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.
|
Support Care Cancer
|
2008
|
0.80
|
|
176
|
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.79
|
|
177
|
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.
|
Lung Cancer
|
2008
|
0.79
|
|
178
|
Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.
|
Ann Thorac Surg
|
2003
|
0.78
|
|
179
|
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
|
Clin Drug Investig
|
2006
|
0.78
|
|
180
|
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
|
Nucl Med Biol
|
2007
|
0.78
|
|
181
|
Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians.
|
Am J Hematol
|
2010
|
0.78
|
|
182
|
A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2007
|
0.78
|
|
183
|
Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage.
|
Radiology
|
2003
|
0.78
|
|
184
|
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
|
Lung Cancer
|
2006
|
0.77
|
|
185
|
Prognostic marker analysis in pediatric intracranial ependymomas.
|
J Neurooncol
|
2015
|
0.77
|
|
186
|
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
|
J Thorac Oncol
|
2008
|
0.77
|
|
187
|
O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
|
J Neurooncol
|
2013
|
0.77
|
|
188
|
Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.
|
Cancer Invest
|
2002
|
0.75
|
|
189
|
Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332.
|
Am J Clin Oncol
|
2004
|
0.75
|
|
190
|
Resection of vestibular schwannomas.
|
J Neurosurg
|
2011
|
0.75
|
|
191
|
Clinical data simplified.
|
J Neurosurg
|
2011
|
0.75
|
|
192
|
Epidemiology.
|
J Neurosurg
|
2011
|
0.75
|
|
193
|
Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography".
|
J Thorac Oncol
|
2015
|
0.75
|
|
194
|
Subarachnoid hemorrhage trials.
|
J Neurosurg
|
2012
|
0.75
|
|
195
|
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.
|
Lung Cancer
|
2004
|
0.75
|
|
196
|
The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost.
|
Cancer Invest
|
2012
|
0.75
|